Harvard Bioscience Inc Dossier
Qualitative Analysis
Business overview
Harvard Bioscience, Inc. (Nasdaq: HBIO) is a leading global developer, manufacturer, and seller of technologies, products, and services designed to enable fundamental advances in life science applications. The company's comprehensive portfolio spans two primary product families: Cellular and Molecular Technology (CMT), which accounted for approximately 46% of global revenues in fiscal year 2025, and Preclinical, which accounted for approximately 54%. Harvard Bioscience serves a diverse customer base, including renowned academic institutions, government laboratories, and leading pharmaceutical, biotechnology, and contract research organizations (CROs) globally. The company is currently undergoing a strategic evolution from a traditional life science tools provider into a leading enabler of translational science, aligning its operations to support the industry's transition toward New Approach Methodologies (NAMs).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Evolving from a traditional life science tools provider into a leading enabler of translational science by focusing on New Approach Methodologies (NAMs) and human-relevant preclinical tools.
Expected impact: Enables customers to generate more predictive, human-relevant data earlier in drug development, driving higher-margin product mix and recurring revenue.
Consolidating U.S. manufacturing operations by closing the Holliston, MA facility and transitioning production to the Minneapolis, MN hub, while relocating certain international operations to Germany, Sweden, and the UK.
Expected impact: Expected to yield approximately $3 million in cost savings in 2027 and $4 million in annual savings starting in 2028 through reduced overhead, SKU rationalization, and improved asset utilization.
Driving commercial adoption of key newly introduced platforms, specifically the MeshMEA organoid platform, BTX Electroporation, and SoHo Telemetry systems.
Expected impact: Deepens reach into the biopharma sector, shifting product mix to higher-margin consumables and recurring revenue streams.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Secured a $40 million credit facility consisting of three term loans (including a $7.5 million convertible note) to retire existing debt, extend maturities to 2029, and add BroadOak Partner Bill Snider to the Board of Directors.
Terms: $40 million credit facility funded on December 17, 2025, with Term Loan C ($7.5 million) convertible into common stock at $1.00 per share, and warrants issued to purchase 2 million shares at $0.50 per share.